As pharma biggies like Ranbaxy and Dr Reddy’s Lab announce plans to tap the regulated biotech drug market, mid-sized players in the segment also seem to harbour such ambitions. Hyderabad-based mid-sized biotech firm Bharat Biotech International is finalising plans to roll out drugs in Europe and US. Initially, the company will initiate European trials on three products which will be soon filed to the European Medicines Agency (EMEA) for regulatory approval. It is also in talks with a couple of US pharma companies to enter into a technology and marketing partnership. As far as US plans go, Bharat Biotech will enter into a tie-up with a US bio-pharma company for joint drug development and marketing. Bharat Biotech exports its products to Kenya, Zambia, Peru, Bolivia, Philippines, Bangladesh, Kenya, Vietnam, Malaysia and Columbia. This apart, it has seven products in Phase II trials in areas like Japanese encephalitis, malaria vaccine, rotavirus vaccine and anti-infective. Future projects are in areas like combination vaccines, bio-antibiotics, combination probiotics and chikungunya vaccine.